Profile: Impax Laboratories Inc (IPXL.O)
17 Nov 2017
Impax Laboratories, Inc., incorporated on March 23, 1995, is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments, which include Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Impax Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
The Company is focused on developing, manufacturing, selling and distributing solid dose and alternative dosage form products covering a range of therapeutic areas and drug-delivery mechanisms or product development formulations. It also develops, manufactures, sells and distributes specialty generic pharmaceuticals. It sells and distributes generic pharmaceutical products through over four sales channels, such as the Impax Generics sales channel, which includes generic pharmaceutical prescription products it sells directly to wholesalers, retail drug chains, and others; Rx Partner sales channel, which includes generic prescription products sold through unrelated third-party pharmaceutical entities pursuant to alliance and collaboration agreements; Private Label sales channel, which includes generic pharmaceutical over-the-counter (OTC) and prescription products it sells to unrelated third parties and in-turn sells the product under their own label, and OTC Partner sales channel, which includes sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical companies pursuant to alliance, collaboration and supply agreements. As of December 31, 2016, the Company marketed 207 generic pharmaceutical products representing dosage variations of 72 various pharmaceutical compounds through its Impax Generics division, and five other generic pharmaceutical products, representing dosage variations of two different pharmaceutical compounds, through its alliance and collaboration agreement partners.
Impax Specialty Pharma
The Company's Impax Specialty Pharma segment is focused on the development and promotion through its specialty sales force of branded pharmaceutical products for the treatment of central nervous system (CNS) disorders, which include migraine, multiple sclerosis, PD and postherpetic neuralgia. The Company's branded pharmaceutical product portfolio consists of commercial CNS products and development stage projects. The Impax Specialty Pharma segment is also engaged in the sale and distribution of four other branded products, including Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches, and Emverm (mebendazole) 100 milligram chewable tablets, indicated for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infection.
The Company competes with Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lannett Company, Inc., Lupin Pharmaceuticals, Inc., Endo International plc and Sandoz.
Impax Laboratories Inc
30831 Huntwood Ave
HAYWARD CA 94544-7003
Company Web Links
- BRIEF-Impax Laboratories says board of co amended and restated bylaws of co
- BRIEF-Impax Q3 adjusted earnings per share $0.23
- BRIEF-Impax gets FDA approval for generic Renvela tablets
- UPDATE 3-Amneal, Impax combine to tackle generic drug pricing pressure
- BRIEF-IMPAX TO PAY AMNEAL $45 MLN IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES